신경면역약 시장 시장 예측(-2030년) : 제품 유형별, 적응증별, 지역별 세계 분석

According to Stratistics MRC, the Global Neuroimmunology Drugs Market is accounted for $23.87 billion in 2023 and is expected to reach $45.05 billion by 2030 growing at a CAGR of 9.5% during the forecast period. The market for neuroimmunology drugs is mostly focused on the treatment of illnesses involving the neurological and immune systems. This covers conditions that affect the neurological system, such as neuromyelitis optica (NMO), multiple sclerosis (MS), and other autoimmune illnesses. Many of the neurological disorders in this area fall within the category of autoimmune illnesses, in which the immune system misidentifies and attacks nervous system components, including the myelin sheath in multiple sclerosis (MS).

Market Dynamics:

Driver:

Increasing incidence of neuroimmunological disorders

As more people receive diagnoses for neuroimmunological illnesses, there will be a greater number of patients in need of care thus the need for neuroimmunology medications is fueled by this. Increased efforts are being made in research and development to identify more effective therapies as a result of the rising occurrence of these conditions. Pharmaceutical corporations allocate resources towards the creation of novel medications to cater to the growing number of patients. The creation of novel medicines is aided by the requirement to serve a wider patient population and to enhance treatment outcomes; scientists and pharmaceutical companies investigate fresh strategies and cutting-edge medication prospects.

Restraint:

High development costs

Research & development investment may be discouraged by high development costs and it may be financially difficult for startups and smaller pharmaceutical companies to launch or maintain medication development projects for neuroimmunological illnesses. In order to recover development expenses and generate a profit, neuroimmunology pharmaceutical companies could set their prices at premium levels. Thus, the excessive medicine costs may make treatment less effective by limiting patient access and affordability.

Opportunity:

Innovative drug developments

New drug targets, routes, and possible treatments are found as a result of scientific advances. This motivates the creation of novel medications and therapeutic modalities for neuroimmunological illnesses. Research improvements enable collaboration among academic institutions, research groups, and pharmaceutical businesses. Moreover, the knowledge exchange and medication development are accelerated by this group effort and research progresses in identifying certain cellular and molecular targets linked to neuroimmunological diseases. As a result, specific treatments that target the underlying causes of various illnesses and modify the immune response are developed.

Threat:

Intense rivalry

Competition that is too fierce might put pressure on pricing because businesses would drop the price of their drugs to get or keep market share. This may have an effect on the profitability of medication research, even while it can help patients by saving money. Drug research and approval processes may be hurried by pharmaceutical corporations in an effort to stay competitive, raising questions about their efficacy and safety. Patient safety as well as industry confidence may be jeopardized by this. To mitigate the possible adverse consequences of market competition, regulatory supervision, quality benchmarks, and a dedication to therapeutic advancement while upholding rigorous R&D standards are crucial.

COVID-19 Impact

Lockdowns and other limitations caused several research activities including clinical trials and laboratory research to be postponed or hindered. This slowed down the development of on-going neuroimmunology medication initiatives. Some pharmaceutical firms may have changed their focus away from developing drugs for neuroimmunology and instead concentrated their research efforts and resources toward COVID-19-related therapies and vaccines. This resulted in possible shortages and production delays of pharmaceuticals thus negatively impacted the market growth.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is estimated to have a lucrative growth, as these disease modifying treatments for neuroimmunological conditions including multiple sclerosis (MS) and neuromyelitis optica (NMO), monoclonal antibodies are frequently used. With the goal of lowering inflammation and suppressing the inflammatory response, these mAbs may be able to delay the course of the illness and avoid relapses. A major factor in many neuroimmunological illnesses is inflammation and inflammation can be lessened by monoclonal antibodies, which can aid with discomfort relief and stop more nerve tissue damage. Certain mAbs function by preventing the autoimmune system from attacking nervous system elements like the myelin sheath thus they aid in preventing harm to the neurological system by doing this.

The multiple sclerosis segment is expected to have the highest CAGR during the forecast period

The multiple sclerosis segment is anticipated to witness the highest CAGR growth during the forecast period, as it is one of the most common neurological disorders in the market for neuroimmunology medications is multiple sclerosis (MS). The protective myelin layer that envelops nerve fibres in the central nervous system (CNS) is wrongly attacked by the immune system in multiple sclerosis (MS), an autoimmune illness. Numerous neurological symptoms are caused by this illness. Moreover novel treatments are being developed and current medications are being repurposed for the treatment of multiple sclerosis as a result of on-going research thus the goals of these cutting-edge treatments are better results and more treatment alternatives.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to neuroimmunological diseases like multiple sclerosis, neuromyelitis optica, and other autoimmune nervous system illnesses have become more common in the Asia-Pacific area. Each nation and area has a different precise prevalence as a result of improved treatment options, early diagnosis, and growing awareness of neuroimmunological illnesses. The management of neuroimmunological illnesses is being improved by a number of regional governments. This entails providing money for research, expanding the infrastructure for healthcare, and encouraging early detection and intervention.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period; owing to the clinical trials for medications linked to neuroimmunology which are mostly conducted in North America. It's a desirable place to do clinical research because of its strong healthcare system, research institutes, and varied patient base. The U.S. Food and Drug Administration (FDA) and Health Canada are two regulatory bodies that guarantee the safety and effectiveness of neuroimmunology medications, creating a well-established regulatory framework for drug approval. In North America, a large number of patients have health insurance, which can help to lower out-of-pocket treatment expenses and improve access to neuroimmunology medications.

Key players in the market

Some of the key players profiled in the Neuroimmunology Drugs Market include: Biogen, Hoffmann-La Roche Ltd, T3D Therapeutics, Novartis AG, Celgene Corp, Merck KGaA, Johnson & Johnson, Eisai Co Ltd, Sanofi, Actelion Pharmaceuticals Ltd., ImmunoBrain Checkpoint, Lundbeck, Eli Lilly, AstraZeneca, UCB SA, AB Science S.A., AstronauTx, Genetech Inc, Inflammasome Therapeutics and TauRX Therapeutics Ltd

Key Developments:

In September 2023, Biogen Inc has completed the acquisition of Reata Pharmaceuticals, Inc. a company focused on developing therapeutics that regulates cellular metabolism and inflammation in serious neurologic diseases.

In June 2023, Roche announced that they had entered into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc. The agreement includes the development, manufacturing and commercialisation rights in the US and Japan for Telavant's RVT-3101.

In April 2023, T3D Therapeutics, Inc. a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer's disease (AD), announced the initiation of dosing in a Phase 2 clinical study of neurometabolic regulator

Product Types Covered:

• Monoclonal Antibodies
• Small Molecules
• Recombinant Protein
• Cytokines
• Lymphocytes
• Other Product Types

Indications Covered:

• Multiple Sclerosis
• Alzheimer's Disease
• Parkinson's Disease
• Myasthenia Gravis
• Guillain-Barre Syndrome
• Neuromyelitis Optica Spectrum Disorder
• Amyotrophic Lateral Sclerosis
• Chronic Inflammatory Demyelinating Polyradiculoneuropathy
• Other Indications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Neuroimmunology Drugs Market, By Product Type

• 5.1 Introduction
• 5.2 Monoclonal Antibodies
• 5.3 Small Molecules
• 5.4 Recombinant Protein
• 5.5 Cytokines
• 5.6 Lymphocytes
• 5.7 Other Product Types

6 Global Neuroimmunology Drugs Market, By Indication

• 6.1 Introduction
• 6.2 Multiple Sclerosis
• 6.3 Alzheimer's Disease
• 6.4 Parkinson's Disease
• 6.5 Myasthenia Gravis
• 6.6 Guillain-Barre Syndrome
• 6.7 Neuromyelitis Optica Spectrum Disorder
• 6.8 Amyotrophic Lateral Sclerosis
• 6.9 Chronic Inflammatory Demyelinating Polyradiculoneuropathy
• 6.10 Other Indications

7 Global Neuroimmunology Drugs Market, By Geography

• 7.1 Introduction
• 7.2 North America
  • 7.2.1 US
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 Italy
  • 7.3.4 France
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 New Zealand
  • 7.4.6 South Korea
  • 7.4.7 Rest of Asia Pacific
• 7.5 South America
  • 7.5.1 Argentina
  • 7.5.2 Brazil
  • 7.5.3 Chile
  • 7.5.4 Rest of South America
• 7.6 Middle East & Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 UAE
  • 7.6.3 Qatar
  • 7.6.4 South Africa
  • 7.6.5 Rest of Middle East & Africa

8 Key Developments

• 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 8.2 Acquisitions & Mergers
• 8.3 New Product Launch
• 8.4 Expansions
• 8.5 Other Key Strategies

9 Company Profiling

• 9.1 Biogen
• 9.2 Hoffmann-La Roche Ltd
• 9.3 T3D Therapeutics
• 9.4 Novartis AG
• 9.5 Celgene Corp
• 9.6 Merck KGaA
• 9.7 Johnson & Johnson
• 9.8 Eisai Co Ltd
• 9.9 Sanofi
• 9.10 Actelion Pharmaceuticals Ltd.
• 9.11 ImmunoBrain Checkpoint
• 9.12 Lundbeck
• 9.13 Eli Lilly
• 9.14 AstraZeneca
• 9.15 UCB SA
• 9.16 AB Science S.A.
• 9.17 AstronauTx
• 9.18 Genetech Inc
• 9.19 Inflammasome Therapeutics
• 9.20 TauRX Therapeutics Ltd